Trade KalVista Pharmaceuticals, Inc. - KALV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 10.65 |
| Open | 10.68 |
| 1-Year Change | 9.09% |
| Day's Range | 10.68 - 11.18 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 18, 2024 | 10.65 | 0.12 | 1.14% | 10.53 | 10.93 | 10.53 |
| Sep 17, 2024 | 10.53 | -0.23 | -2.14% | 10.76 | 11.11 | 10.41 |
| Sep 16, 2024 | 10.73 | -0.29 | -2.63% | 11.02 | 11.15 | 10.49 |
| Sep 13, 2024 | 11.10 | 0.62 | 5.92% | 10.48 | 11.20 | 10.36 |
| Sep 12, 2024 | 10.42 | -0.28 | -2.62% | 10.70 | 10.86 | 10.41 |
| Sep 11, 2024 | 10.69 | -0.33 | -2.99% | 11.02 | 11.34 | 10.61 |
| Sep 10, 2024 | 11.20 | -0.57 | -4.84% | 11.77 | 11.93 | 11.17 |
| Sep 9, 2024 | 11.82 | -0.15 | -1.25% | 11.97 | 12.77 | 11.67 |
| Sep 6, 2024 | 12.29 | -0.38 | -3.00% | 12.67 | 12.93 | 12.19 |
| Sep 5, 2024 | 12.84 | 0.21 | 1.66% | 12.63 | 12.98 | 12.57 |
| Sep 4, 2024 | 12.87 | 0.65 | 5.32% | 12.22 | 12.99 | 12.22 |
| Sep 3, 2024 | 12.33 | -0.95 | -7.15% | 13.28 | 13.46 | 12.08 |
| Aug 30, 2024 | 13.35 | 0.36 | 2.77% | 12.99 | 13.43 | 12.61 |
| Aug 29, 2024 | 12.96 | 0.08 | 0.62% | 12.88 | 13.28 | 12.77 |
| Aug 28, 2024 | 12.86 | 0.38 | 3.04% | 12.48 | 12.99 | 12.48 |
| Aug 27, 2024 | 12.65 | -0.19 | -1.48% | 12.84 | 12.91 | 12.38 |
| Aug 26, 2024 | 13.03 | 0.60 | 4.83% | 12.43 | 13.05 | 12.41 |
| Aug 23, 2024 | 12.60 | 0.39 | 3.19% | 12.21 | 12.67 | 11.99 |
| Aug 22, 2024 | 12.39 | 0.01 | 0.08% | 12.38 | 12.50 | 11.90 |
| Aug 21, 2024 | 12.53 | 0.07 | 0.56% | 12.46 | 12.71 | 12.14 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
KalVista Pharmaceuticals, Inc. Company profile
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Plasma kallikrein is a serine protease enzyme, which is an early mediator of inflammation and edema. The body modulates the inflammatory effects of plasma kallikrein through a circulating inhibitor protein called C1-esterase inhibitor (C1-INH). The Company is primary focused on the development of the oral plasma kallikrein inhibitors for HAE. It has two drug program candidates in clinical trials. The Company’s DME program is focused on the development of an intravitreally administered small molecule plasma kallikrein inhibitor, KVD001, which completed a Phase II trial.
Financial summary
BRIEF: For the nine months ended 31 January 2022, Kalvista Pharmaceuticals Inc revenues was not reported. Net loss increased 86% to $58.2M. Higher net loss reflects Research and development increase of 73% to $51M (expense), General and administrative increase of 80% to $18.8M (expense), foriegn exchange gain/loss decrease from $715K (income) to $529K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.75 to -$2.38.
| Industry: | Biopharmaceuticals |
55 Cambridge Pkwy Ste 901E
CAMBRIDGE
MASSACHUSETTS 02142-1234
US
News
BoE Preview: no change expected but forward guidance will be key
The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.
14:53, 19 September 2024
FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion
Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.
11:30, 19 September 2024
Bank of Japan Preview
The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.
09:40, 17 September 2024
FOMC Decision Preview
As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.
09:48, 16 September 2024
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com